ACADIA PHARMACEUTICALS INC. Operating Lease, Liability, Noncurrent
ACADIA PHARMACEUTICALS INC. (ACAD) had Operating Lease, Liability, Noncurrent of $59.55 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:OperatingLeaseLiabilityNoncurrent · last filed 2026-08-05
- 2026-06-30: Operating Lease, Liability, Noncurrent $59.55M.
- 2026-03-31: Operating Lease, Liability, Noncurrent $39.00M.
- 2025-12-31: Operating Lease, Liability, Noncurrent $40.55M.
- 2025-09-30: Operating Lease, Liability, Noncurrent $43.03M.
| Period end | Operating Lease, Liability, Noncurrent |
|---|---|
| 2026-06-30 | $59.55M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $39.00M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $40.55M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $43.03M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $44.60M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $44.63M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $42.04M 10-K · filed 2026-02-26 |
| 2024-09-30 | $40.42M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $47.19M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $49.19M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $47.80M 10-K · filed 2025-02-27 |
| 2023-09-30 | $48.10M 10-Q · filed 2023-11-03 |
| 2023-06-30 | $49.78M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $51.44M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $52.70M 10-K · filed 2024-02-28 |
| 2022-09-30 | $53.77M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $54.69M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $55.48M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $56.13M 10-K · filed 2023-02-28 |
| 2021-09-30 | $57.68M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $59.13M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $60.58M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $44.46M 10-K · filed 2022-03-01 |
| 2020-09-30 | $45.34M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $5.67M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $6.09M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $6.36M 10-K · filed 2021-02-25 |
| 2019-09-30 | $6.38M 10-Q · filed 2019-10-31 |
| 2019-06-30 | $6.74M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $6.75M 10-Q · filed 2019-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |